Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/stat3 signaling pathway

Journal of Investigative Dermatology

Volumn 131, Issue 6, 2011, Pages 1331-1338

  Krejsgaard, Thorbjørn ^a   Ralfkiaer, Ulrik ^b   Clasen Linde, Erik ^b   Eriksen, Karsten W ^a   Kopp, Katharina L ^a   Bonefeld, Charlotte M ^a   Geisler, Carsten ^a   Dabelsteen, Sally ^c   Wasik, Mariusz A ^d   Ralfkiaer, Elisabeth ^b   Woetmann, Anders ^a   Odum, Niels ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR BETA; JANUS KINASE 3; SMALL INTERFERING RNA; STAT3 PROTEIN;

ARTICLE; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE; LYMPHOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERUM; SIGNAL TRANSDUCTION; SKIN; T LYMPHOCYTE;

EID: 79956003644     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2011.27     Document Type: Article

References (51)

1. Ciree A, Michel L, Camilleri-Broet S et al. (2004) Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome). Int J Cancer 112:113-20 (Pubitemid 39249498)
2. Cornejo MG, Kharas MG, Werneck MB et al. (2009) Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood 113:2746-54
3. Daliani D, Ulmer RA, Jackow C et al. (1998) Tumor necrosis factor-alpha and interferon-gamma, but not HTLV-I tax, are likely factors in the epidermotropism of cutaneous T-cell lymphoma via induction of interferon-inducible protein-10. Leuk Lymphoma 29:315-28 (Pubitemid 28282328)
4. Dobbeling U, Dummer R, Laine E et al. (1998) Interleukin-15 is an autocrine/ paracrine viability factor for cutaneous T-cell lymphoma cells. Blood 92:252-8 (Pubitemid 28303200)
5. Doherty SD, Ni X, Doherty CB et al. (2006) Abnormal expression of interleukin-23 in mycosis fungoides/Sezary syndrome lesions. Arch Dermatol Res 298:353-6
6. Eriksen KW, Kaltoft K, Mikkelsen G et al. (2001) Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia 15:787-93 (Pubitemid 32492702)
7. Ferenczi K, Fuhlbrigge RC, Pinkus J et al. (2002) Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol 119:1405-10 (Pubitemid 36005628)
8. Gaffen SL (2009) Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 9:556-67
9. Genovese MC, Van den Bosch F, Roberson SA et al. (2010) LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 62:929-39
10. Girardi M, Heald PW, Wilson LD (2004) The pathogenesis of mycosis fungoides. N Engl J Med 350:1978-88 (Pubitemid 38580201)
11. Gjerdrum LM, Woetmann A, Odum N et al. (2007) FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia 21:2512-8 (Pubitemid 350148895)
12. Hansen ER, Vejlsgaard GL, Lisby S et al. (1991) Epidermal interleukin 1 alpha functional activity and interleukin 8 immunoreactivity are increased in patients with cutaneous T-cell lymphoma. J Invest Dermatol 97:818-23
13. Harper EG, Guo C, Rizzo H et al. (2009) Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol 129:2175-83
14. Hwang ST, Janik JE, Jaffe ES et al. (2008) Mycosis fungoides and Sezary syndrome. Lancet 371:945-57
15. Ji Y, Zhang W (2010) Th17 cells: positive or negative role in tumor? Cancer Immunol Immunother 59:979-87
16. Kaltoft K, Bisballe S, Rasmussen HF et al. (1987) A continuous T-cell line from a patient with Sezary syndrome. Arch Dermatol Res 279:293-8 (Pubitemid 17092161)
17. Kanda N, Koike S, Watanabe S (2005) IL-17 suppresses TNF-alpha-induced CCL27 production through induction of COX-2 in human keratinocytes. J Allergy Clin Immunol 116:1144-50 (Pubitemid 41571801)
18. Kasprzycka M, Zhang Q, Witkiewicz A et al. (2008) Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes. J Immunol 181:2506-12
19. Kim EJ, Hess S, Richardson SK et al. (2005) Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 115:798-812 (Pubitemid 40489380)
20. Koga C, Kabashima K, Shiraishi N et al. (2008) Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol 128:2625-30
21. Kopp KL, Kauczok CS, Lauenborg B et al. (2010) COX-2-dependent PGE(2) acts as a growth factor in mycosis fungoides (MF). Leukemia 24:1179-85
22. Korn T, Bettelli E, Oukka M et al. (2009) IL-17 and Th17 cells. Annu Rev Immunol 27:485-517
23. Krejsgaard T, Gjerdrum LM, Ralfkiaer E et al. (2008) Malignant Tregs express low molecular splice forms of FOXP3 in Sezary syndrome. Leukemia 22:2230-9
24. Krejsgaard T, Vetter-Kauczok CS, Woetmann A et al. (2009) Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma. Blood 113:5896-904
25. Krejsgaard T, Vetter-Kauczok CS, Woetmann A et al. (2006) Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia 20:1759-66 (Pubitemid 44574987)
26. Leroy S, Dubois S, Tenaud I et al. (2001) Interleukin-15 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Dermatol 144:1016-23 (Pubitemid 34203355)
27. Marzec M, Halasa K, Kasprzycka M et al. (2008) Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells. Cancer Res 68:1083-91 (Pubitemid 351272226)
28. Mazur G, Wozniak Z, Wrobel T et al. (2004) Increased angiogenesis in cutaneous T-cell lymphomas. Pathol Oncol Res 10:34-6 (Pubitemid 38506610)
29. Miossec P, Korn T, Kuchroo VK (2009) Interleukin-17 and type 17 helper T cells. N Engl J Med 361:888-98
30. Murugaiyan G, Saha B (2009) Protumor vs antitumor functions of IL-17. J Immunol 183:4169-75
31. Nograles KE, Zaba LC, Guttman-Yassky E et al. (2008) Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 159:1092-102
32. Pesu M, Laurence A, Kishore N et al. (2008) Therapeutic targeting of Janus kinases. Immunol Rev 223:132-42 (Pubitemid 351986189)
33. Schmuth M, Neyer S, Rainer C et al. (2002) Expression of the C-C chemokine MIP-3 alpha/CCL20 in human epidermis with impaired permeability barrier function. Exp Dermatol 11:135-42 (Pubitemid 36934631)
34. Sommer VH, Clemmensen OJ, Nielsen O et al. (2004) In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia 18:1288-95 (Pubitemid 39023140)
35. Vacca A, Moretti S, Ribatti D et al. (1997) Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9. Eur J Cancer 33:1685-92 (Pubitemid 28123494)
36. Vergier B, De MA, Beylot-Barry M et al. (2000) Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas. Blood 95:2212-8 (Pubitemid 30167716)
37. Vonderheid EC, Bernengo MG, Burg G et al. (2002) Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 46:95-106 (Pubitemid 34073484)
38. Vowels BR, Lessin SR, Cassin M et al. (1994) Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol 103:669-73 (Pubitemid 24350134)
39. Weaver CT, Hatton RD, Mangan PR et al. (2007) IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 25:821-52 (Pubitemid 46697925)
40. West K (2009) CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr Opin Investig Drugs 10:491-504
41. Willemze R, Jaffe ES, Burg G et al. (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-85 (Pubitemid 40656118)
42. Wilson LJ (2010) Recent patents in the discovery of small molecule inhibitors of JAK3. Expert Opin Ther Pat 20:609-23
43. Woetmann A, Lovato P, Eriksen KW et al. (2007) Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins. Blood 109:3325-32 (Pubitemid 46572520)
44. Yamanaka K, Clark R, Dowgiert R et al. (2006a) Expression of interleukin-18 and caspase-1 in cutaneous T-cell lymphoma. Clin Cancer Res 12:376-82 (Pubitemid 43166124)
45. Yamanaka K, Clark R, Rich B et al. (2006b) Skin-derived interleukin-7 contributes to the proliferation of lymphocytes in cutaneous T-cell lymphoma. Blood 107:2440-5 (Pubitemid 43345565)
46. Yoshihara K, Yamada H, Hori A et al. (2007) IL-15 exacerbates collagen-induced arthritis with an enhanced CD4+ T cell response to produce IL-17. Eur J Immunol 37:2744-52 (Pubitemid 47578293)
47. Yue P, Turkson J (2009) Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs 18:45-56
48. Zhang Q, Nowak I, Vonderheid EC et al. (1996) Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci USA 93:9148-53
49. Zhang Q, Raghunath PN, Vonderheid E et al. (2000) Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am J Pathol 157:1137-46
50. Ziolkowska M, Koc A, Luszczykiewicz G et al. (2000) High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 164: 2832-8 (Pubitemid 30115519)
51. Zou W, Restifo NP (2010) T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 10:248-56